StockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)

StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued to investors on Thursday. The firm issued a hold rating on the stock.

Several other equities research analysts have also recently weighed in on the stock. Lake Street Capital lowered their price objective on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Ekso Bionics in a report on Tuesday, March 4th.

Ekso Bionics Price Performance

NASDAQ:EKSO opened at $0.44 on Thursday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The company has a 50-day moving average of $0.52 and a 200-day moving average of $0.75. Ekso Bionics has a 52 week low of $0.34 and a 52 week high of $1.53. The company has a market capitalization of $10.89 million, a price-to-earnings ratio of -0.67 and a beta of 1.43.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). The company had revenue of $5.09 million for the quarter, compared to the consensus estimate of $5.05 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. As a group, equities research analysts anticipate that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.